kelch repeat and BTB domain containing 13Genealiases: HCG1645727 · NEM6
Q-omics provides the consensus-scored KBTBD13 profile across patient tissues and cancer cell-line models. KBTBD13 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, KBTBD13 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, KBTBD13 RNA expression shows 9,455 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight DLBC, COAD, and SARC as cancer lineages where KBTBD13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KBTBD13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KBTBD13 survival associations across molecular data types. KBTBD13 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KBTBD13 RNA expression–survival associations across cancer types. High KBTBD13 expression shows unfavorable associations in DLBC, ACC, KIRP, COAD and LUAD, but favorable associations in SCLC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for KBTBD13 RNA expression.
This table summarizes KBTBD13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KBTBD13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KBTBD13 shows lower tumor expression in COAD, BLCA, HNSC, UCEC, KIRP and LUSC. The COAD box plot shows higher KBTBD13 RNA expression in normal versus tumor tissue (log2 FC = −0.060, t-test p < 0.001).
This table shows molecular features associated with KBTBD13 in patient tissues and cancer cell lines. In patient samples, KBTBD13 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set. In cancer cell lines, KBTBD13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
